Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk
Quenez O, Schramm C, Cassinari K, Nicolas A, Groeneveld J, Huguet G, Grenier-Boley B, Hulsman M, Walters GB, de Rojas I, Rovelet-Lecrux A, Feuillette S, et al.. American Journal of Human Genetics, 2026-08-26
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Copy-number variants (CNVs) are major contributors to human disease. In Alzheimer disease (AD), APP duplications cause autosomal-dominant forms, but the role of CNVs in non-monogenic AD remains poorly characterized. We analyzed rare CNVs (frequency SCARF2 = 0.34 [0.21; 0.53]; mega-p value = 5.52 × 10 -7 ). SCARF2 overexpression significantly increased amyloid-β uptake, congruent with duplication-associated decreased AD risk. We conclude that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 deletions, including some found in DiGeorge syndrome, increase AD risk. Conversely, we identify 22q11.21 duplication as a strong AD-risk-decreasing factor.
What this study adds
Evidence grade: Moderate
This is a case-control study of 22,319 participants. This study found that rare copy-number variants in some Alzheimer's-associated genes and deletions at 22q11.21 increase Alzheimer's risk, while duplication at 22q11.21 decreases risk. Reported effect size: 22q11.21 duplication (SCARF2) OR 0.34 (95% CI 0.21-0.53) for AD; ABCA1 loss-of-function OR 5.77.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Quenez, O., Schramm, C., Cassinari, K., Nicolas, A., Groeneveld, J., Huguet, G., et al. (2026). Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk. American Journal of Human Genetics. https://doi.org/10.1016/j.ajhg.2026.07.013
Vancouver
Quenez O, Schramm C, Cassinari K, Nicolas A, Groeneveld J, Huguet G, et al. Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk. American Journal of Human Genetics. 2026. doi:10.1016/j.ajhg.2026.07.013. PMID: 42648288.
BibTeX
@article{quenez2026-42648288,
author = {Quenez, O. and Schramm, C. and Cassinari, K. and Nicolas, A. and Groeneveld, J. and Huguet, G. and Grenier-Boley, B. and Hulsman, M. and Walters, G. B. and de Rojas, I. and Rovelet-Lecrux, A. and Feuillette, S. and others},
title = {{Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk}},
journal = {American Journal of Human Genetics},
year = {2026},
doi = {10.1016/j.ajhg.2026.07.013},
pmid = {42648288},
url = {https://doi.org/10.1016/j.ajhg.2026.07.013}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- SCARF2 overexpression significantly increased amyloid-β uptake, congruent with duplication-associated decreased AD risk.
- We conclude that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 deletions, including some found in DiGeorge syndrome, increase AD risk.
Why it matters
This study found that rare copy-number variants in some Alzheimer's-associated genes and deletions at 22q11.21 increase Alzheimer's risk, while duplication at 22q11.21 decreases risk. It also found that SCARF2 overexpression increased amyloid-beta uptake, consistent with the duplication's protective effect.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcase-control
- Participants22,319
- Effect size22q11.21 duplication (SCARF2) OR 0.34 (95% CI 0.21-0.53) for AD; ABCA1 loss-of-function OR 5.77
- Evidence strengthModerate
How this study scored 57/100
Published in a peer-reviewed journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, senior author's track record and free to read, so those were left out: it earned 51 of the 90 points we could judge it on, which is 57 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Human Genetics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 22,319 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Rebecca Sims holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42648288) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 51 / 90 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 51 of the 90 points we could judge it on is 57 out of 100. |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.